About the Skin Cancer Session
Skin cancer is one of the most common types of cancer and can range from mild to life-threatening. Skin cancer occurs when abnormal cells in the skin divide and grow uncontrollably. It is the most common form of cancer in the U.S., with more than 3.5 million cases diagnosed each year. There are several types of skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma. All three types arise from the epidermis, the outermost layer of skin. Melanoma, the most deadly form of skin cancer, is typically caused by overexposure to the sun’s ultraviolet (UV) rays or ultraviolet radiation from tanning beds, and forms when melanocytes, the cells that produce the pigment melanin, become cancerous. Basal cell carcinoma typically arises in areas of the skin that are frequently exposed to the sun and is typically slow-growing and rarely spreads to other parts of the body. Squamous cell carcinoma is less common than other forms of skin cancer, and typically appears as a scaly, red patch, often on the arms, legs, ears, and face. Early detection is key in treating skin cancer. Dermatologists often recommend monthly self-examinations and regular dermatologist appointments to look for changes in skin color or any new or suspicious lesions. If skin cancer is detected early, it is usually treatable. Treatment options may include topical medications, excisional surgery, radiation therapy, or phototherapy. Prevention is also important when it comes to skin cancer. The American Academy of Dermatology recommends that people protect their skin from the sun, wear sunscreen with at least an SPF of 30, and seek shade when the sun’s rays are at their strongest. Regular use of these measures can dramatically reduce the risk of developing skin cancer.
Featured Speakers — Skin Cancer 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Skin Cancer Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Skin Cancer Conference 2027
Present Your Research
Oral and poster slots for original Skin Cancer work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Skin Cancer research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same program, same certificate.
Join IDC 2027 for the Skin Cancer track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Skin Cancer Conference 2027 — FAQs
What is the Skin Cancer track at IDC 2027?
The Skin Cancer track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Skin Cancer. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Skin Cancer sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Skin Cancer are all welcome — whether presenting or attending.
Can I present my research in the Skin Cancer track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Skin Cancer sessions?
Yes. IDC 2027 is a hybrid conference — attend the Skin Cancer track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.

